Combination therapy consisting of a BRAF inhibitor and MEK inhibitor has become the standard‐of‐care for melanoma patients harboring the BRAFV600E mutation.3 However, it is still difficult to achieve long‐lasting remissions for one‐third of patients, owing to the advanced stage or heterogeneity of the disease and/or drug resistance. Here, MAP2K7 is linked to melanoma.